Select Inhaled Respiratory Agents

Policy # 00526
Original Effective Date: 01/01/2017
Current Effective Date: 08/14/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Inhaled Corticosteroid Products
Based on review of available data, the Company may consider the inhaled corticosteroid products Aerospan®‡ (flunisolide), Alvesco®‡ (ciclesonide), Asmanex™‡ Twishaler®‡ (mometasone furoate), Asmanex™‡ HFA (mometasone furoate), Armonair™ Respiclick®‡ (fluticasone propionate), Armonair Digihaler™ (fluticasone propionate), and branded generic Fluticasone Propionate HFA to be eligible for coverage** when the below patient selection criterion is met:

Patient Selection Criteria
Coverage eligibility will be considered for Aerospan (flunisolide), Alvesco (ciclesonide), Asmanex Twishaler (mometasone furoate), Asmanex HFA (mometasone furoate), Armonair Respiclick (fluticasone propionate), Armonair Digihaler (fluticasone propionate), or branded generic Fluticasone Propionate HFA when the following criterion is met:

- There is clinical evidence or patient history that suggests the use of Arnuity™‡ Ellipta®‡ (fluticasone furoate), Flovent®‡ Diskus®‡ (fluticasone propionate), Flovent®‡ HFA (fluticasone propionate), QVAR®‡ (beclomethasone dipropionate), or Pulmicort Flexhaler®‡ (budesonide) will be/was ineffective or will/did cause an adverse reaction to the patient.

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of Aerospan (flunisolide), Alvesco (ciclesonide), Asmanex Twishaler (mometasone furoate), Asmanex HFA (mometasone furoate), Armonair Respiclick (fluticasone propionate), Armonair Digihaler (fluticasone propionate), or branded generic Fluticasone Propionate HFA WITHOUT clinical evidence or patient history that
Select Inhaled Respiratory Agents

Policy #  00526
Original Effective Date:  01/01/2017
Current Effective Date:  08/14/2023

suggests the use of Arnuity Ellipta (fluticasone furoate), Flovent Diskus (fluticasone propionate), Flovent HFA (fluticasone propionate), QVAR (beclomethasone propionate), or Pulmicort Flexhaler (budesonide) will be/was ineffective or will/did cause an adverse reaction to the patient to be **not medically necessary.**

**When Services May Be Eligible for Coverage**
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:
- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

**Inhaled Long Acting Beta Agonists (LABAs)**
Based on review of available data, the Company may consider the inhaled long acting beta agonists Arcapta™ Neohaler™ (indacaterol) and Foradil® Aerolizer® (formoterol fumarate) to be **eligible for coverage** when the below patient selection criterion is met:

**Patient Selection Criteria**
Coverage eligibility will be considered for Arcapta Neohaler (indacaterol) or Foradil Aerolizer (formoterol fumarate) when the following criterion is met:
- There is clinical evidence or patient history that suggests the use of Striverdi® Respimat® (olodaterol) or Serevent® Diskus (salmeterol xinafoate) will be/was ineffective or will/did cause an adverse reaction to the patient.

**When Services Are Considered Not Medically Necessary**
Based on review of available data, the Company considers the use of Arcapta Neohaler (indacaterol) or Foradil Aerolizer (formoterol fumarate) **WITHOUT** clinical evidence or patient history that suggests the use of Striverdi Respimat (olodaterol) or Serevent Diskus (salmeterol xinafoate) will be/was ineffective or will/did cause an adverse reaction to the patient to be **not medically necessary.**

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Nebulized Long Acting Chronic Obstructive Pulmonary Disease (COPD) Products

Based on review of available data, the Company may consider the nebulized long acting COPD products Brovana®‡ (arformoterol tartrate), generic arformoterol tartrate, Perforomist®‡ (formoterol fumarate), generic formoterol fumarate, Lonhala™ Magnair™ (glycopyrrolate), and Yupelri®‡ (revefenacin) to be eligible for coverage** when the below patient selection criteria are met:

Patient Selection Criteria

Coverage eligibility will be considered for Brovana (arformoterol tartrate), generic arformoterol tartrate, Perforomist (formoterol fumarate), generic formoterol fumarate, Lonhala Magnair (glycopyrrolate), or Yupelri (revefenacin) when the following criteria are met:

- For all requested products: There is clinical evidence or patient history that suggests the use of TWO of the following preferred bronchodilating agents for COPD: generic fluticasone propionate/salmeterol diskus®, Wixela™ Inhub® (fluticasone propionate/salmeterol), Serevent Diskus (salmeterol xinafoate), Spiriva® Respimat® (tiotropium bromide), Spiriva HandiHaler® (tiotropium bromide), Anoro® Ellipta (umeclidinium/vilanterol), Stiolto® Respimat (tiotropium bromide/olodaterol), Striverdi Respimat (olodaterol), Incruse® Ellipta (umeclidinium), or Symbicort® (budesonide/formoterol fumarate dihydrate) will be/was ineffective or will/did cause an adverse reaction to the patient; AND

- If the request is for Brovana (arformoterol tartrate) or Perforomist (formoterol fumarate), the following criterion must ALSO be met: There is clinical evidence or patient history that suggests the use of the generic equivalent product (arformoterol for Brovana requests or formoterol for Perforomist requests) will be/was ineffective or will/did cause an adverse reaction to the patient.

**Note that the use of more than one generic equivalent of Advair® Diskus only counts as one product
Select Inhaled Respiratory Agents

Policy # 00526
Original Effective Date: 01/01/2017
Current Effective Date: 08/14/2023

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of Brovana (arformoterol tartrate), generic arformoterol tartrate, Perforomist (formoterol fumarate), generic formoterol fumarate, Lonhala Magnair (glycopyrrolate), or Yupelri (revefenacin) WITHOUT clinical evidence or patient history that suggests the use of TWO of the following preferred bronchodilating agents for COPD: generic fluticasone propionate/salmeterol diskus, Wixela Inhub (fluticasone propionate/salmeterol), Serevent Diskus (salbutamol xinafoate), Spiriva Respimat (tiotropium bromide), Spiriva HandiHaler (tiotropium bromide), Anoro Ellipta (umeclidinium/vilanterol), Stiolto Respimat (tiotropium bromide/olodaterol), Striverdi Respimat (olodaterol), Incruse Ellipta (umeclidinium), or Symbicort (budesonide/formoterol fumarate dihydrate) will be/was ineffective or will/did cause an adverse reaction to the patient to be not medically necessary.**

Based on review of available data, the Company considers the use of Brovana (arformoterol tartrate), or Perforomist (formoterol fumarate) WITHOUT clinical evidence or patient history that suggests the use of the generic equivalent product (arformoterol for Brovana requests or formoterol for Perforomist requests) will be/was ineffective or will/did cause an adverse reaction to the patient to be not medically necessary.**

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

• Benefits are available in the member’s contract/certificate, and
• Medical necessity criteria and guidelines are met.

Inhaled Corticosteroid/Long Acting Beta Agonist Combination Products (ICS/LABAs)
Based on review of available data, the Company may consider the inhaled corticosteroid/long acting beta agonist combination products AirDuo™ Respliclick (fluticasone propionate/salmeterol), AirDuo DigiHaler (fluticasone propionate/salmeterol), branded generic Budesonide/Formoterol Fumarate, Advair Diskus (fluticasone propionate/salmeterol), branded generic Fluticasone furoate/Vilanterol, and branded generic Fluticasone propionate/Salmeterol HFA to be eligible for coverage** when the below patient selection criterion is met:
Select Inhaled Respiratory Agents

Policy #: 00526
Original Effective Date: 01/01/2017
Current Effective Date: 08/14/2023

Patient Selection Criteria
Coverage eligibility will be considered for AirDuo Respiclick (fluticasone propionate/salmeterol), AirDuo Digihaler (fluticasone propionate/salmeterol), branded generic Budesonide/Formoterol Fumarate, Advair Diskus (fluticasone propionate/salmeterol), branded generic Fluticasone furoate/Vilanterol, or branded generic Fluticasone propionate/Salmeterol HFA when the following criterion is met:

- There is clinical evidence or patient history that suggests the use of generic fluticasone propionate/salmeterol diskus, Wixela Inhub (fluticasone propionate/salmeterol), Advair HFA (fluticasone propionate/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol), Symbicort (budesonide/formoterol fumarate dihydrate), the branded generic Fluticasone Propionate/Salmeterol (branded generic of AirDuo Respiclick), or Dulera (mometasone furoate/formoterol furoate) will be/was ineffective or will/did cause an adverse reaction to the patient.

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of AirDuo Respiclick (fluticasone propionate/salmeterol), AirDuo Digihaler (fluticasone propionate/salmeterol), branded generic Budesonide/Formoterol Fumarate, Advair Diskus (fluticasone propionate/salmeterol), branded generic Fluticasone furoate/Vilanterol, or branded generic Fluticasone propionate/Salmeterol HFA WITHOUT clinical evidence or patient history that suggests the use of generic fluticasone propionate/salmeterol diskus, Wixela Inhub (fluticasone propionate/salmeterol), Advair HFA (fluticasone propionate/salmeterol), Breo Ellipta (fluticasone furoate/vilanterol), Symbicort (budesonide/formoterol fumarate dihydrate), the branded generic Fluticasone Propionate/Salmeterol (branded generic of AirDuo Respiclick), or Dulera (mometasone furoate/formoterol furoate) will be/was ineffective or will/did cause an adverse reaction to the patient to be not medically necessary.**

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.

Page 5 of 16
Select Inhaled Respiratory Agents

Policy #  00526  
Original Effective Date:  01/01/2017  
Current Effective Date:  08/14/2023  

**Inhaled Long Acting Antimuscarinic Agents (LAMAs)**
Based on review of available data, the Company may consider the inhaled long acting antimuscarinic agents Tudorza®‡ Pressair®‡ (aclidinium bromide) and Seebri™‡ Neohaler (glycopyrrolate) to be eligible for coverage** when the below patient selection criterion is met:

**Patient Selection Criteria**
Coverage eligibility will be considered for Tudorza Pressair (aclidinium bromide) or Seebri Neohaler (glycopyrrolate) when the following criterion is met:

- There is clinical evidence or patient history that suggests the use of Spiriva Respimat (tiotropium bromide), Spiriva HandiHaler (tiotropium bromide), or Incruse Ellipta (umeclidinium) will be/was ineffective or will/did cause an adverse reaction to the patient.

**When Services Are Considered Not Medically Necessary**
Based on review of available data, the Company considers the use of Tudorza Pressair (aclidinium bromide) or Seebri Neohaler (glycopyrrolate) WITHOUT clinical evidence or patient history that suggests the use of Spiriva Respimat (tiotropium bromide), Spiriva HandiHaler (tiotropium bromide), or Incruse Ellipta (umeclidinium) will be/was ineffective or will/did cause an adverse reaction to the patient to be not medically necessary,**

**When Services May Be Eligible for Coverage**
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

**Inhaled Long Acting Antimuscarinic Agent/Long Acting Beta Agonist Combination Products (LAMA/LABAs)**
Based on review of available data, the Company may consider the inhaled long acting antimuscarinic agent/long acting beta agonist combination products Bevespi Aerosphere™‡ (glycopyrrolate/formoterol fumarate), Utibron™‡ Neohaler (indacaterol/glycopyrrolate), and Duaklir®‡ Pressair (aclidinium/formoterol fumarate) to be eligible for coverage** when the below patient selection criterion is met:
Select Inhaled Respiratory Agents

Policy # 00526
Original Effective Date: 01/01/2017
Current Effective Date: 08/14/2023

Patient Selection Criteria
Coverage eligibility will be considered for Bevespi Aerosphere (glycopyrrolate/formoterol fumarate), Utibron Neohaler (indacaterol/glycopyrrolate), or Duaklir Pressair (aclidinium/formoterol fumarate) when the following criterion is met:

• There is clinical evidence or patient history that suggests the use of Anoro Ellipta (umeclidinium/vilanterol) or Stiolto Respimat (tiotropium bromide/olodaterol) will be/was ineffective or will/did cause an adverse reaction to the patient.

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of Bevespi Aerosphere (glycopyrrolate/formoterol fumarate), Utibron Neohaler (indacaterol/glycopyrrolate), or Duaklir Pressair (aclidinium/formoterol fumarate) WITHOUT clinical evidence or patient history that suggests the use of Anoro Ellipta (umeclidinium/vilanterol) or Stiolto Respimat (tiotropium bromide/olodaterol) will be/was ineffective or will/did cause an adverse reaction to the patient to be not medically necessary.**

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

• Benefits are available in the member’s contract/certificate, and
• Medical necessity criteria and guidelines are met.

Inhaled Short Acting Beta Agonists (SABAs)
Based on review of available data, the Company may consider the short acting beta agonists Proventil®‡ HFA (albuterol sulfate), Xopenex®‡ HFA (levalbuterol tartrate), ProAir®‡ Digihaler (albuterol sulfate), branded generic Levalbuterol HFA, branded generic Albuterol HFA, and ProAir HFA (albuterol sulfate) to be eligible for coverage** when the below patient selection criterion is met:

Patient Selection Criteria
Coverage eligibility will be considered for Proventil HFA (albuterol sulfate), Xopenex HFA (levalbuterol tartrate), ProAir Digihaler (albuterol sulfate), branded generic Levalbuterol HFA,
Select Inhaled Respiratory Agents

Policy # 00526
Original Effective Date: 01/01/2017
Current Effective Date: 08/14/2023

branded generic Albuterol HFA, or ProAir HFA (albuterol sulfate) when the following criterion is met:
  - There is clinical evidence or patient history that suggests the use of ProAir RespiClick (albuterol sulfate), Ventolin®‡ HFA (albuterol sulfate), or generic albuterol sulfate HFA will be/was ineffective or will/did cause an adverse reaction to the patient.

When Services Are Considered Not Medically Necessary
Based on review of available data, the Company considers the use of Proventil HFA (albuterol sulfate), Xopenex HFA (levalbuterol tartrate), ProAir Digihaler (albuterol sulfate), branded generic Levalbuterol HFA, branded generic Albuterol HFA, or ProAir HFA (albuterol sulfate) WITHOUT clinical evidence or patient history that suggests the use of ProAir RespiClick (albuterol sulfate), Ventolin HFA (albuterol sulfate), or generic albuterol sulfate HFA will be/was ineffective or will/did cause an adverse reaction to the patient to be not medically necessary.**

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:
  - Benefits are available in the member’s contract/certificate, and
  - Medical necessity criteria and guidelines are met.

Inhaled Long Acting Antimuscarinic Agents/Corticosteroids/Long Acting Beta Agonists (LAMA/ICS/LABAs)
Based on review of available data, the Company may consider the inhaled long acting antimuscarinic agents/corticosteroids/long acting beta agonist Breztri Aerosphere™‡ (budesonide/glycopyrrolate/formoterol fumarate) to be eligible for coverage** when the below patient selection criterion is met:

Patient Selection Criteria
Coverage eligibility will be considered for Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) when the following criterion is met:
Select Inhaled Respiratory Agents

Policy #  00526
Original Effective Date:  01/01/2017
Current Effective Date:  08/14/2023

- There is clinical evidence or patient history that suggests the use of Trelegy™ Ellipta (fluticasone furoate/umeclidinium/vilanterol) will be/was ineffective or will/did cause an adverse reaction to the patient.

When Services Are Considered Not Medically Necessary

Based on review of available data, the Company considers the use of Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) WITHOUT clinical evidence or patient history that suggests the use of Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) will be/was ineffective or will/did cause an adverse reaction to the patient to be not medically necessary.**

Schematic

<table>
<thead>
<tr>
<th>Class</th>
<th>Non-Preferred Products</th>
<th>Preferred Products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inhaled Corticosteroids (ICS)</td>
<td>Aerospan</td>
<td>Arnuity Ellipta</td>
</tr>
<tr>
<td></td>
<td>Alvesco</td>
<td>Flovent Diskus</td>
</tr>
<tr>
<td></td>
<td>Asmanex Twisthaler</td>
<td>Flovent HFA</td>
</tr>
<tr>
<td></td>
<td>Asmanex HFA</td>
<td>QVAR</td>
</tr>
<tr>
<td></td>
<td>Armonair Resplicick</td>
<td>Pulimcort Flexhaler</td>
</tr>
<tr>
<td></td>
<td>Armonair Dighaler</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Branded Generic Fluticasone Propionate HFA</td>
<td></td>
</tr>
<tr>
<td>Inhaled Long Acting Beta Agonists (LABAs)</td>
<td>Arcapta Neohaler</td>
<td>Striverdi Respimat</td>
</tr>
<tr>
<td></td>
<td>Foradil Aerolizer</td>
<td>Serevent Diskus</td>
</tr>
<tr>
<td>Nebulized Long Acting COPD Products</td>
<td>Brovana arformoterol tartrate</td>
<td>Generic fluticasone/salmeterol diskus</td>
</tr>
<tr>
<td></td>
<td>Perforomist formoterol fumarate</td>
<td>Wixela Inhub</td>
</tr>
<tr>
<td></td>
<td>Lonhala Magnair Yupelri</td>
<td>Serevent Diskus</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spiriva Respimat</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spiriva HandiHaler</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anoro Ellipta</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stiolto Respimat</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Striverdi Respimat</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Incrise Ellipta</td>
</tr>
</tbody>
</table>
## Select Inhaled Respiratory Agents

**Policy #** 00526  
**Original Effective Date:** 01/01/2017  
**Current Effective Date:** 08/14/2023

<table>
<thead>
<tr>
<th><strong>Inhaled Corticosteroids/Long Acting Beta Agonists (ICS/LABAs)</strong></th>
<th><strong>Symbicort</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AirDuo Respiceclick</td>
<td>Generic fluticasone/salmeterol diskus</td>
</tr>
<tr>
<td>AirDuo Digihaler</td>
<td>Wixela Inhub</td>
</tr>
<tr>
<td>Branded Generic Budesonide/Formoterol Fumarate</td>
<td>Advair HFA</td>
</tr>
<tr>
<td>Advair Diskus</td>
<td>Breo Ellipta</td>
</tr>
<tr>
<td>Branded Generic Fluticasone/Vilanterol</td>
<td>Symbicort</td>
</tr>
<tr>
<td>Branded Generic Fluticasone/Salmeterol HFA</td>
<td>Fluticasone/Salmeterol-(branded generic of AirDuo Respiceclick)</td>
</tr>
<tr>
<td><strong>Inhaled Long Acting Antimuscarinic Agents (LAMAs)</strong></td>
<td><strong>Symbicort</strong></td>
</tr>
<tr>
<td>Tudorza Pressair</td>
<td>Spiriva Respimat</td>
</tr>
<tr>
<td>Seebri Neohaler</td>
<td>Spiriva HandiHaler</td>
</tr>
<tr>
<td><strong>Inhaled Long Acting Antimuscarinic Agents/Long Acting Beta Agonists (LAMA/LABA)</strong></td>
<td><strong>Symbicort</strong></td>
</tr>
<tr>
<td>Utibron Neohaler</td>
<td>Anoro Ellipta</td>
</tr>
<tr>
<td>Bevespi Aerosphere</td>
<td>Stiolto Respimat</td>
</tr>
<tr>
<td>Duaklir Pressair</td>
<td><strong>Inhaled Short Acting Beta Agonists (SABAs)</strong></td>
</tr>
<tr>
<td>Proventil HFA</td>
<td>ProAir RespiClick</td>
</tr>
<tr>
<td>Xopenex HFA</td>
<td>Ventolin HFA</td>
</tr>
<tr>
<td>Branded Generic Albuterol HFA</td>
<td>Generic albuterol HFA</td>
</tr>
<tr>
<td>ProAir Digihaler</td>
<td><strong>Inhaled Long Acting Antimuscarinic Agents/Corticosteroids/Long Acting Beta Agonists (LAMA/ICS/LABAs)</strong></td>
</tr>
<tr>
<td>Branded Generic Levalbuterol HFA</td>
<td>Breztri Aerosphere</td>
</tr>
<tr>
<td>ProAir HFA</td>
<td>Trelegy Ellipta</td>
</tr>
</tbody>
</table>

*Note that the use of more than one generic equivalent of Advair Diskus only counts as one product*
Select Inhaled Respiratory Agents

Policy #  00526
Original Effective Date:  01/01/2017
Current Effective Date:  08/14/2023

Background/Overview
The various products mentioned in this policy are approved for use in COPD and/or asthma patients, depending on the particular product.

Rationale/Source
This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

The patient selection criteria presented in this policy takes into consideration clinical evidence or patient history that suggests the preferred products listed in this policy will be ineffective or cause an adverse reaction to the patient. Based on a review of the available data and in the absence of any of the caveats mentioned, there is no advantage of using the non-preferred agents mentioned in this policy over the preferred agents mentioned in this policy.

References
Select Inhaled Respiratory Agents

Policy # 00526
Original Effective Date: 01/01/2017
Current Effective Date: 08/14/2023


©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Select Inhaled Respiratory Agents

Policy #  00526
Original Effective Date:  01/01/2017
Current Effective Date:  08/14/2023

Select Inhaled Respiratory Agents

Policy # 00526
Original Effective Date: 01/01/2017
Current Effective Date: 08/14/2023


**Policy History**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/08/2016</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>09/21/2016</td>
<td>Medical Policy Implementation Committee approval. New policy.</td>
</tr>
<tr>
<td>08/03/2017</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>08/23/2017</td>
<td>Medical Policy Implementation Committee approval. Moved Stiolto Respimat to a preferred agent. New drug (AirDuo) placed in the non-preferred position. Branded generic of AirDuo (fluticasone/salmeterol) place in preferred position. Adjust existing criteria based on these changes.</td>
</tr>
<tr>
<td>01/04/2018</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>01/17/2018</td>
<td>Medical Policy Implementation Committee approval. Placed new drug, Armonair Respliclick, in the non-preferred column for ICS products. Added a new section for new drug class (LAMA/ICS/LABA) and placed Trelegy Ellipta in the preferred column.</td>
</tr>
<tr>
<td>06/07/2018</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>06/20/2018</td>
<td>Medical Policy Implementation Committee approval. Switched Dulera to a preferred product. Added Lonhala Magnair to the policy. Changed nebulized long acting beta agonists to nebulized long acting COPD products. Added Advair Diskus and Symbicort as preferred options prior to Brovana, Perforomist, and Lonhala Magnair.</td>
</tr>
<tr>
<td>06/06/2019</td>
<td>Medical Policy Committee review</td>
</tr>
<tr>
<td>06/19/2019</td>
<td>Medical Policy Implementation Committee approval. Added the branded generic Albuterol HFA as a non-preferred option. Added the generics for Advair Diskus (generic, Wixela Inhub) as preferred options for therapy. Added a new product, Yupelri, to the policy in a non-preferred position.</td>
</tr>
<tr>
<td>06/04/2020</td>
<td>Medical Policy Committee review</td>
</tr>
</tbody>
</table>
| 06/10/2020   | Medical Policy Implementation Committee approval. Removed Advair Diskus from the preferred products as it now has generic equivalents. Added Budesonide/Formoterol Fumarate branded generic to the policy (Authorized

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Select Inhaled Respiratory Agents

Policy # 00526
Original Effective Date: 01/01/2017
Current Effective Date: 08/14/2023

Generic of Symbicort) as a non-preferred option in the ICS/LABA class. Added generic albuterol HFA as a preferred option in the SABA class. Added ProAir Digihaler as a non-preferred option in the SABAs. Added Duaklir Pressair as a non-preferred option in LAMA/LABA class.

09/03/2020 Medical Policy Committee review
09/09/2020 Medical Policy Implementation Committee approval. Added Advair Diskus brand as a non-preferred product. Changed ProAir HFA to non-preferred.
01/07/2021 Medical Policy Committee review
01/13/2021 Medical Policy Implementation Committee approval. Added three new FDA approved products to the non-preferred category: AirDuo Digihaler, Armonair Digihaler, and Breztri Aerosphere.
08/05/2021 Medical Policy Committee review
08/11/2021 Medical Policy Implementation Committee approval. Changed Pulmicort Flexhaler from non-preferred to preferred. Added two new generic products, arformoterol and formoterol nebulized products, to the policy.
08/04/2022 Medical Policy Committee review
08/10/2022 Medical Policy Implementation Committee approval. Added branded generic Fluticasone Propionate HFA and branded generic Fluticasone-Vilanterol to the policy as non-preferred agents.
07/06/2023 Medical Policy Committee review
07/12/2023 Medical Policy Implementation Committee approval. Added branded generic Fluticasone propionate/Salmeterol HFA to policy as a non-preferred agent.

Next Scheduled Review Date: 07/2024

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

A. In accordance with nationally accepted standards of medical practice;
B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services.
Select Inhaled Respiratory Agents

Policy # 00526
Original Effective Date: 01/01/2017
Current Effective Date: 08/14/2023

at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.